Veeva Vault enables Daiichi Sankyo to standardize business processes
worldwide
PLEASANTON, Calif. & TOKYO--(BUSINESS WIRE)--
Veeva
Systems (NYSE:VEEV) today announced that Daiichi Sankyo Company,
Limited (hereinafter, Daiichi Sankyo) based in Japan, selected Veeva
Vault eTMF, Veeva
Vault QualityDocs, and Veeva
Vault Submissions to unify content management throughout its
research and development (R&D) operations worldwide.
The unique multitenant cloud capabilities of Veeva Vault enable Daiichi
Sankyo to easily streamline management of its critical content,
providing external partners, such as CROs, the same level of secure
access and collaboration as internal operations teams. Another key
benefit was the ability of Veeva’s support organization to implement
Veeva Vault in a short period of time to drive greater consistency
globally at every stage of product development, from clinical to quality
to regulatory.
“Veeva Vault was superior to every solution we evaluated in the market,”
said Yasuhiro Ikeda, the Vice President, IT Strategy Department. “Veeva
gives us a true cloud platform to stay current on the latest technology
capabilities. With Veeva conducting installation qualification (IQ) and
operational qualification (OQ) processes, we expect to save resources
and costs not having to upgrade projects every several years. Lastly,
Veeva provided a sandbox environment during our selection phase for
users to test technical and business capabilities. The high satisfaction
among our users was one of the deciding factors in selecting Veeva.”
“Veeva Vault makes it easier for pharmaceutical companies based in Japan
to accelerate their global efforts,” said Takashi Okamura, general
manager of Veeva Japan. “We are honored to globally support Daiichi
Sankyo and deliver greater visibility, transparency, and efficiency in
their global pharmaceutical operations.”
Additional Information
For more on Veeva Vault, visit: veeva.com/vault
Stay
updated on the latest Veeva news on LinkedIn: linkedin.com/company/veeva-systems
Follow
@veevasystems on Twitter: twitter.com/veevasystems
Like
Veeva on Facebook: facebook.com/veevasystems
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of
innovative pharmaceutical products to address diversified, unmet medical
needs of patients in both mature and emerging markets. With over 100
years of scientific expertise and a presence in more than 20 countries,
Daiichi Sankyo and its 16,000 employees around the world draw upon a
rich legacy of innovation and a robust pipeline of promising new
medicines to help people. In addition to a strong portfolio of medicines
for hypertension and thrombotic disorders, under the Group’s 2025 Vision
to become a “Global Pharma Innovator with Competitive Advantage in
Oncology,” Daiichi Sankyo research and development is primarily focused
on bringing forth novel therapies in oncology, including
immuno-oncology, with additional focus on new horizon areas, such as
pain management, neurodegenerative diseases, heart and kidney diseases,
and other rare diseases. For more information, please visit: www.daiichisankyo.com.
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 400 customers, ranging from the
world's largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit www.veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended April 30, 2016. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160823005541/en/
Source: Veeva Systems Inc.